IBB Fact Sheet: iShares Biotechnology ETF
Share
$199.54
close, Nov 20, 2026
Over the year to Nov 19, 2026, IBB returned +23.6% in total and charged 0.44% a year.
- 1-year total return
- +21.7%
- to Nov 20, 2026
- Expense ratio
- 0.44%
- a year
- Net assets
- $10.8bn
- on Nov 19, 2026
- Net flow, last 5 trading days
- +$165m
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
IBB $12,355 +23.6% · PBUS $10,892 +8.9% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−5.7%
3 months−6.6%
Year to date+18.3%
1 year+21.7%
3 years+70.4%
5 years+30.7%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
GILEAD SCIENCES9.32%
AMGEN INC8.36%
VERTEX PHARMACEUTICALS7.83%
REGENERON PHARMACEUTICALS6.63%
MODERNA5.28%
ARGENX SE ADR3.79%
NATERA2.83%
BIOGEN2.63%
BEONE MEDICINES AG2.44%
INSMED2.25%
IBB top ten by weight, 51.4% of the fund, of its 245 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 245 stocks in biotech, 43% of its weight in S&P 500 companies · First traded Feb 12, 2001 · Benchmark Its own holdings, as of Nov 19, 2026